Navigation Links
Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
Date:2/26/2008

SCOTTSDALE, Ariz., Feb. 26 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled MedPredict Thought Leader Insight & Analysis: Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel debates tough questions facing drug developers:

-- How should rheumatologists sequence/stack biologicals? What will

challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell?

-- How big of a benefit will oral dosing provide in this patient

population? Syk? Jak? p38? CCR? Will orals move RA treatment into

the community?

-- What do they hear from Pharma? What will Wyeth do when they return to

Amgen the rights to etanercept? How strong is AstraZeneca's

commitment to arthritis?

-- Why is it so hard to treat gout?

"There continue to be significant unmet needs in this market," says MedPredict President Jeffrey D. Berk. "According to our Panelists, only half of RA patients achieve remission on their first biological therapy and these remissions aren't durable. Even with completely new options many patients are left under-satisfied and demanding better results from their physicians. This report sheds light on these unmet needs and reveals Panelists' views of the most promising candidates."

Drugs/Companies mentioned in this report: allopurinol; febuxostat (Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Schering-Plough/Essex); Actemra (tocilizumab; Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc/anti-BR3 MAb Biogen/Genentech); LymphoStat-B(R) (belimumab; Human Genome Sciences/GSK); Atacicept (TACI-Ig; ZymoGenetics/Merck-Serono); BMS-582949 (BMS); 856553 (GSK); CP-690550 (Pfizer); INCB18424 (Incyte); tamatinib (R788; Rigel); baminercept (BG9924; Biogen); MLN-3897 (Millennium/Sanofi-Aventis); AZD5672 (AstraZeneca); RWJ-445380 (Alza/J&J); AZD9056 (AstraZeneca); everolimus (RAD-001; Novartis); MM-093 (Merrimack)

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize
2. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
3. CardioDynamics Provides 2007 Shareholder Meeting Update
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
6. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
7. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
8. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. NxStage Medical Provides Update on Medisystems Acquisition
11. VaxGen Files 2006 Financial Statements and Provides Cash Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Lajollacooks4u has become a rising hotspot for specialized team building events in ... Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled from ... Each event kicks off with an olive oil and salt-tasting competition. From there, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... , ... May 25, 2016 , ... WEDI, the nation’s ... exchange, today announced that Charles W. Stellar has been named by the WEDI Board ... since January 2016. As an executive leader with more than 35 years of experience ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a range ... by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented method ... , The novel method, developed by WPI faculty members Raymond Page, PhD, professor ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/11/2016)... 2016 --> ... "Image Recognition Market by Technology (Pattern Recognition), by Component ... Deployment Type (On-Premises and Cloud), by Industry Vertical and ... MarketsandMarkets, the global market is expected to grow from ... by 2020, at a CAGR of 19.1%. ...
Breaking Biology News(10 mins):